What is Brief History of Pacira Company?

How did Pacira reshape post-surgical pain care?

Pioneering a long‑acting, non‑opioid delivery platform, Pacira transformed postoperative analgesia and challenged opioid dependence. Founded in 2006 in New Jersey, its DepoFoam technology enabled sustained local anesthetic release and altered clinical practice.

Pacira grew from a single‑technology startup into a diversified acute‑care pharmaceutical company, leading the postsurgical local anesthetic market by 2025 with flagship therapies and strategic product expansion.

What is Brief History of Pacira Company? — Founded in 2006, Pacira launched DepoFoam‑based EXPAREL and expanded its portfolio through R&D and acquisitions; see Pacira Porter's Five Forces Analysis for product and market context.

Pacira BioSciences began in December 2006 when investors and life-science executives led by David Stack moved to address a large postsurgical pain treatment gap by adapting DepoFoam technology to create a long-acting bupivacaine injectable.

Founding Story

Pacira company history traces to the acquisition of SkyePharma’s injectable unit and the ambition to commercialize EXPAREL as a safer alternative to opioid-heavy postoperative care.

• Founded December 2006 via purchase of SkyePharma’s injectable business for approximately $35,000,000 upfront plus milestones
• Founders led by David Stack targeted postoperative analgesia gaps vs patient-controlled analgesia pumps and oral opioids
• Acquisition included San Diego manufacturing assets and DepoFoam IP enabling development of long-acting bupivacaine (EXPAREL)
• Early capital from MPM Capital and OrbiMed Advisors supported transition from licensing model to integrated commercial pharmaceutical company

Pivotal elements in the Pacira pharmaceutical timeline include a 505(b)(2) regulatory pathway chosen for EXPAREL, commercialization launch following FDA approval, and scaling of sales infrastructure to capture hospital and ambulatory surgery center markets; these moves defined Pacira corporate background and early growth metrics.

Initial investor consortium valued the opportunity based on clinical need and delivery technology; by 2015 EXPAREL had become the company’s primary revenue driver, reflecting the evolution of Pacira pharmaceutical company from startup to established commercial-stage firm.

For more on the firm’s commercial model and income sources see Revenue Streams & Business Model of Pacira

Complete Pacira Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Following its formation, Pacira rapidly scaled clinical development and commercialization of EXPAREL, culminating in FDA approval in October 2011 and a commercial launch in April 2012 that drove fast revenue growth and market adoption.

IPO and FDA Approval

Pacira completed its IPO in February 2011, raising approximately $42,000,000. FDA approval for EXPAREL in October 2011 enabled postsurgical analgesia via local administration.

Commercial Launch and Sales Scaling

The April 2012 commercial launch prompted aggressive sales-force expansion targeting anesthesiologists and orthopedic surgeons, producing strong first-year sales and uptake in opioid-sparing protocols.

Manufacturing Capacity Expansion

By 2014 Pacira expanded manufacturing in San Diego to meet demand; EXPAREL became standard in high-volume procedures like total knee arthroplasty, supporting growing revenues.

Label Expansion and New Indications

In 2018 the FDA approved EXPAREL for interscalene brachial plexus block, widening use in shoulder surgeries and strengthening the Pacira pharmaceutical timeline.

Strategic Acquisitions

Pacira acquired MyoScience in 2019 for $120,000,000, adding the iovera cryoneurolysis system, and purchased Flexion Therapeutics in late 2021 for $450,000,000, bringing Zilretta into its portfolio.

Transition to Multi-Platform Pain Solutions

These moves shifted Pacira from a single-product firm into a multi-platform non-opioid pain company, with annual revenues approaching $600,000,000 by the early 2020s.

For a comparative view and further context on market positioning, see Competitors Landscape of Pacira

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

Milestones, Innovations and Challenges trace Pacira company history from its DepoFoam roots through EXPAREL approvals, regulatory and patent battles, and a 2024 strategic shift toward partnerships and ERAS implementation.

Pacira's core innovation is the DepoFoam delivery system: microscopic lipid-based chambers that encapsulate bupivacaine and release it as lipid layers erode, enabling EXPAREL's prolonged analgesia. The company advanced formulations and clinical programs that supported label expansions and ERAS integration, backed by clinical data showing multi-day analgesic benefit and reductions in opioid use.

DepoFoam sustained-release

DepoFoam encapsulation provided controlled release over 72 hours, a first for local anesthetics.

EXPAREL clinical evidence

Randomized trials demonstrated reduced opioid consumption and shorter hospital stays in some surgical settings.

Label expansions

FDA approvals through 2024 included lower extremity nerve blocks and pediatric indications, expanding clinical use.

ERAS partnerships

Strategic alliances with health systems embedded EXPAREL into Enhanced Recovery After Surgery pathways to drive adoption.

Manufacturing and trade secrets

Investments in manufacturing controls and proprietary processes aimed to raise barriers to generic entry post-495 decision.

Commercial model evolution

Shifted from direct sales to partnership-driven deployment to secure institutional contracts and protocol adoption.

Pacira faced regulatory and legal challenges that shaped its corporate trajectory, including the 2014 FDA Warning Letter and ensuing 2015 settlement that defined promotional boundaries. In 2024 the invalidation of the 495 patent triggered generic threats and accelerated legal and business defenses to protect market share.

Regulatory scrutiny

2014 FDA Warning Letter prompted litigation over truthful, non-misleading communications and led to a 2015 settlement clarifying label use.

Patent litigation

August 2024 district court ruling invalidated the 495 patent, enabling generic entrants like eVenus and prompting appeals and defensive strategies.

Market competition

Generics and alternative analgesic approaches intensified pricing and reimbursement pressures, challenging revenue growth.

Commercial adaptation

Company pivoted to partnership-based sales, aiming to lock in ERAS protocols and institutional formularies to sustain volume.

Financial impact

EXPAREL revenue faced headwinds in 2023–2024; Pacira reported adjusted net product sales decline year-over-year but pursued label expansions to offset losses.

Strategic defenses

Focused on protecting newer patents, confidential manufacturing processes, and building clinical evidence to sustain differentiation.

Further detail and strategic analysis appear in this article: Marketing Strategy of Pacira

Pacira Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Timeline and Future Outlook: a concise Pacira company history tracing key milestones from its December 2006 founding through regulatory, commercial and M&A events, recent leadership and legal developments, and near‑term growth drivers tied to policy and new product formats that shape revenue projections into 2026.

Regulatory and market inflection

The NOPAIN Act effective January 2025 is expected to remove major reimbursement barriers for Ambulatory Surgery Centers, enabling wider EXPAREL adoption and supporting projected volume growth in 2025–2026.

Product portfolio expansion

Launch of new 200mg/10mL vials targets soft tissue and outpatient procedures, improving dosing flexibility and addressable market share in surgical analgesia.

Financial outlook to 2026

Analysts modeling post‑NOPAIN adoption and vial expansion project total revenues approaching $800,000,000 by year‑end 2026, assuming continued uptake and manageable generic competition.

Competitive and IP considerations

Patent litigation outcomes and generic entrants remain key risks, but entrenched surgical workflow integration and ongoing R&D provide a defensive moat supporting long‑term positioning.

For a broader Pacira pharmaceutical timeline and company milestones see Brief History of Pacira

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE